List view / Grid view
Enzymatic Therapy, a leading manufacturer of dietary supplements and natural medicines chose to build its own FDA-approved manufacturing facility, with the primary goal of improving product quality, streamlining production, and ultimately ramping up sales growth.
15 December 2016 | By Astell Scientific
Astell Scientific is pleased to announce the launch of a new and improved range of autoclaves...
14 December 2016 | By Cobalt Light Systems
A case study from Astellas Pharma Tech Co. Ltd., Japan, describes how Cobalt’s RapID verifies the ID of raw materials through unopened paper and polyethylene sacks...
Global logistics service provider Yusen Logistics is continuing to grow its network and will open its first location in Switzerland on 1st January 2017.
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Prostate cancer can become resistant to hormone therapy and continue to grow despite treatment. Jevtana (cabazitaxel) is the only remaining chemotherapy...
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Novartis' two pivotal Phase III clinical studies did not meet their primary endpoints to treatment of neovascular age-related macular degeneration...
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Biocartis launched its second liquid biopsy assay, the Idylla ctKRAS Mutation Assay, which was developed in partnership with Merck...
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The VTC Group is pleased to announce a partnership with Deloitte, to create a Deloitte Healthcare Virtual Technology Cluster...
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The results of two recently completed Phase 2a clinical trials that demonstrated significant Alzheimer's disease relevant pharmacological activity...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The new and enhanced SMS for Life 2.0 program will now use smartphone and tablet computers to address key operational challenges at peripheral healthcare...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
Patients with ALK+ advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to placebo...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
It significantly reduced the risk of (the combined primary endpoint) cardiovascular death, non-fatal heart attack or non-fatal stroke by 14% versus placebo...
12 December 2016 | By Niamh Louise Marriott, Digital Editor
The visibility of DC Bead Lumi helps optimise patient treatment by enabling real-time confirmation of bead location during the embolization procedure...
9 December 2016 | By Niamh Louise Marriott, Digital Editor
Pharma Giant Pfizer has been fined a record £84.2 million after it broke competition law by charging excessive and unfair prices to the UK...
